MariMed Statistics
Total Valuation
MariMed has a market cap or net worth of 19.12 million. The enterprise value is 104.26 million.
Important Dates
The last earnings date was Wednesday, November 11, 2026.
| Earnings Date | Nov 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
MariMed has 406.00 million shares outstanding. The number of shares has increased by 3.17% in one year.
| Current Share Class | 406.00M |
| Shares Outstanding | 406.00M |
| Shares Change (YoY) | +3.17% |
| Shares Change (QoQ) | +0.85% |
| Owned by Insiders (%) | 10.78% |
| Owned by Institutions (%) | 0.00% |
| Float | 338.61M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.11 |
| PB Ratio | 0.46 |
| P/TBV Ratio | 6.36 |
| P/FCF Ratio | 2.09 |
| P/OCF Ratio | 1.90 |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
The stock's EV/EBITDA ratio is 8.86, with an EV/FCF ratio of 11.41.
| EV / Earnings | n/a |
| EV / Sales | 0.62 |
| EV / EBITDA | 8.86 |
| EV / EBIT | n/a |
| EV / FCF | 11.41 |
Financial Position
The company has a current ratio of 0.90, with a Debt / Equity ratio of 1.93.
| Current Ratio | 0.90 |
| Quick Ratio | 0.29 |
| Debt / Equity | 1.93 |
| Debt / EBITDA | 7.69 |
| Debt / FCF | 9.91 |
| Interest Coverage | -0.27 |
Financial Efficiency
Return on equity (ROE) is -26.66% and return on invested capital (ROIC) is -1.74%.
| Return on Equity (ROE) | -26.66% |
| Return on Assets (ROA) | -0.70% |
| Return on Invested Capital (ROIC) | -1.74% |
| Return on Capital Employed (ROCE) | -1.69% |
| Weighted Average Cost of Capital (WACC) | 8.10% |
| Revenue Per Employee | 193,167 |
| Profits Per Employee | -17,910 |
| Employee Count | 923 |
| Asset Turnover | 0.83 |
| Inventory Turnover | 2.79 |
Taxes
In the past 12 months, MariMed has paid 4.73 million in taxes.
| Income Tax | 4.73M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -41.13% in the last 52 weeks. The beta is 1.55, so MariMed's price volatility has been higher than the market average.
| Beta (5Y) | 1.55 |
| 52-Week Price Change | -41.13% |
| 50-Day Moving Average | 0.06 |
| 200-Day Moving Average | 0.07 |
| Relative Strength Index (RSI) | 34.03 |
| Average Volume (20 Days) | 1,034,395 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.02 |
Income Statement
In the last 12 months, MariMed had revenue of 167.28 million and -15.51 million in losses. Loss per share was -0.04.
| Revenue | 167.28M |
| Gross Profit | 59.16M |
| Operating Income | -2.20M |
| Pretax Income | -10.74M |
| Net Income | -15.51M |
| EBITDA | 9.61M |
| EBIT | -2.20M |
| Loss Per Share | -0.04 |
Full Income Statement Balance Sheet
The company has 10.36 million in cash and 90.49 million in debt, with a net cash position of -80.12 million or -0.20 per share.
| Cash & Cash Equivalents | 10.36M |
| Total Debt | 90.49M |
| Net Cash | -80.12M |
| Net Cash Per Share | -0.20 |
| Equity (Book Value) | 46.99M |
| Book Value Per Share | 0.10 |
| Working Capital | -6.59M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was 10.08 million and capital expenditures -949,000, giving a free cash flow of 9.13 million.
| Operating Cash Flow | 10.08M |
| Capital Expenditures | -949,000 |
| Depreciation & Amortization | 11.81M |
| Net Borrowing | -4.43M |
| Free Cash Flow | 9.13M |
| FCF Per Share | 0.02 |
Full Cash Flow Statement Margins
Gross margin is 35.37%, with operating and profit margins of -1.32% and -9.27%.
| Gross Margin | 35.37% |
| Operating Margin | -1.32% |
| Pretax Margin | -6.42% |
| Profit Margin | -9.27% |
| EBITDA Margin | 5.74% |
| EBIT Margin | -1.32% |
| FCF Margin | 5.46% |
Dividends & Yields
MariMed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -3.17% |
| Shareholder Yield | -3.17% |
| Earnings Yield | -84.93% |
| FCF Yield | 47.77% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MariMed has an Altman Z-Score of -0.08 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.08 |
| Piotroski F-Score | 3 |